BrainChild Bio, Inc.
BrainChild Bio develops CAR T-cell therapies for central nervous system tumors, prioritizing pediatric brain cancers such as diffuse intrinsic pontine glioma and extending its pipeline to adult tumors including glioblastoma and brain metastases. It aims to create safe and effective treatment options for children and adults with incurable brain tumors.
Facts
- Sectors
- Biotechnology Research
- Employees
- 11–50
- Stage
- Series A
- Founders
- Michael Jensen, MD
Is this your organization? Claim it
BrainChild Bio Raises $116M Series A to Fund Pivotal Phase 2 Trial of BCB-276 CAR T Therapy for DIPG
BrainChild Bio, spun out of Seattle Children’s, is advancing B7-H3–targeting CAR T-cell therapies for incurable pediatric brain tumors and has raised $116 million to fund a pivotal Phase 2 trial of BCB-276 for DIPG.
BrainChild Bio to pursue multi-center Phase 2 pivotal trial of BCB-276, an autologous B7-H3 CAR T therapy for DIPG after positive FDA meeting and Phase 1 Nature Medicine data
BrainChild Bio will advance BCB-276, an autologous B7-H3–targeting CAR T-cell therapy for diffuse intrinsic pontine glioma (DIPG), into a multi-center Phase 2 pivotal trial following a positive FDA Type B meeting and supportive Phase 1 data published in Nature Medicine. The company aims to use this accelerated path toward a Biologics License Application to bring a potential treatment to children and young adults with no approved options.
BrainChild Bio launches pivotal Phase 2 ILLUMINATE trial of BCB-276 CAR T for newly diagnosed pediatric DIPG to support BLA
BrainChild Bio has launched the ILLUMINATE Phase 2 pivotal trial of BCB-276, a B7-H3-targeted autologous CAR T therapy for newly diagnosed pediatric DIPG, enrolling at six U.S. pediatric oncology centers to evaluate efficacy and safety and support a future BLA.
BrainChild Bio’s B7-H3 CAR T Therapy BCB-276 Receives FDA RMAT Designation; Pivotal Phase 2 Planned for Q4 2025
BrainChild Bio’s investigational autologous B7-H3 CAR T-cell therapy BCB-276 received FDA RMAT designation for treating diffuse intrinsic pontine glioma (DIPG), and the company plans a single pivotal Phase 2 trial to support a BLA with dosing expected to begin in Q4 2025. The therapy uses locoregional delivery into cerebrospinal fluid via a reservoir-catheter and follows promising survival results from the BrainChild-03 Phase 1 trial.
FDA Grants Breakthrough Therapy Designation to BrainChild Bio’s B7-H3 CAR T-Cell Therapy BCB-276 for DIPG; Pivotal Phase 2 Planned for Q4 2025
BrainChild Bio’s investigational B7-H3 autologous CAR T-cell therapy BCB-276 received FDA Breakthrough Therapy Designation for treating diffuse intrinsic pontine glioma (DIPG) based on encouraging overall survival data from the Phase 1 BrainChild-03 trial; the company plans a single pivotal Phase 2 trial to support a BLA submission starting in Q4 2025.
BrainChild Bio Raises $116M Series A to Fund Phase 2 Pivotal Trial of BCB-276 for DIPG
BrainChild Bio raised $116 million in a Series A to fund the ILLUMINATE Phase 2 pivotal trial of BCB-276 for diffuse intrinsic pontine glioma (DIPG) and to advance BCB-214 and other CAR T programs for pediatric and adult brain tumors.
Seattle Children’s launches BrainChild Bio to commercialize novel CAR T-cell therapies for pediatric brain tumors, initially targeting DIPG
Seattle Children’s has launched BrainChild Bio, an independently managed company funded initially by Seattle Children’s, to commercialize novel CAR T-cell therapies for pediatric central nervous system tumors and advance ongoing clinical trials focusing first on diffuse intrinsic pontine glioma (DIPG) and other pediatric brain tumors.
People
-
Michael Jensen Founder, Chief Scientific Officer
-
Steven Brugger Executive, Chief Executive Officer